ライフサイエンスコーパス: cycloserine

1 s including beta-lactams, polymyxin B, and d-cycloserine.

2 he algD operon undergoes high induction by D-cycloserine.

3 a complete lack of PalgD-cat induction by D-cycloserine.

4 ularly for toxic second-line drugs such as D-cycloserine.

5 echanism of alanine racemase inactivation by cycloserine.

6 dex increased 100% in the presence of 2 mm l-cycloserine.

7 mptoms worsen, as previously reported with D-cycloserine.

8 ontrolled trial of 50 mg and 100 mg/day of D-cycloserine.

9 anidine and enrichment with penicillin and D-cycloserine.

10 ith response of negative symptoms to 50-mg D-cycloserine.

11 cine(B) site on the NMDA receptor, such as d-cycloserine.

12 in comparison with the enzyme inactivated by cycloserine.

13 ion of the NMDA receptor partial coagonist d-cycloserine.

14 al therapy, the most promising of which is D-cycloserine.

15 sessions, the participants received either D-cycloserine, 100 mg, or a placebo.

16 e mean reduction in negative symptoms with D-cycloserine (23%) was significantly greater than with pl

17 d-cycloserine (25 or 50 mg) or placebo was taken 1 hour be

18 microg/ml; clarithromycin, 1.25 microg/ml; D-cycloserine, 25 microg/ml; ethambutol, 20 microg/ml; and

19 Single administration of D-cycloserine (320 or 1000 microgram/kg) significantly imp

20 rtual reality exposure were augmented with D-cycloserine (50 mg) or alprazolam (0.25 mg) in a double-

21 ia for deficit syndrome were randomized to D-cycloserine, 50 mg/d (n=23) or placebo (n=24) added to t

22 High-dose D-cycloserine (8000 microgram/kg) or MK-801 (10-32 microgr

23 Finally, the effect of D-cycloserine, a cognitive enhancer that clinically enhanc

24 The authors examined whether D-cycloserine, a partial agonist at the glutamatergic N-me

25 In a preliminary dose-finding study, D-cycloserine, a partial agonist at the glycine modulatory

26 D-Cycloserine, a partial agonist at the glycine recognitio

27 This study examined whether d-cycloserine, a partial agonist at the N-methyl-D-asparta

28 d-cycloserine, a partial agonist at the N-methyl-d-asparta

29 Cycloserine acts as a suicide inhibitor of alanine racem

30 The effects of D-cycloserine added to clozapine were assessed and compare

31 ted that the NMDA receptor partial agonist d-cycloserine administered after pavlovian extinction of c

32 Systemic D-cycloserine also selectively reduced intake of quinine-a

33 osure therapy for SAD may be enhanced with d-cycloserine, an agonist at the glutamatergic N-methyl-d-

34 Pretreatment with L-cycloserine, an inhibitor of de novo ceramide synthesis,

35 -propanol and, to a much lesser extent, by L-cycloserine, an inhibitor of de novo ceramide synthesis.

36 l-Cycloserine, an inhibitor of gSPT, inhibited the endocyt

37 Preincubation of cells with either L-cycloserine, an inhibitor of serine palmitoyltransferase

38 l-Cycloserine, an inhibitor that blocks serine palmitoyltr

39 ith an average of 5.3+/-1.3 drugs, including cycloserine, an injectable drug, and a fluoroquinolone.

40 Susceptibility was also increased to cycloserine and bacitracin, but not to fosfomycin or val

41 de, para-aminosalicylic acid, linezolid, and cycloserine and compared with Bactec MGIT results for py

42 e adduct is similar to that formed between d-cycloserine and d-a-AT or alanine racemase (Ala-Rac) in

43 o inhibitors of sphingolipid biosynthesis, L-cycloserine and fumonisin B1, prevented the observed acc

44 ted the assay by performing it to identify D-Cycloserine and furan-based benzene-derived compounds wi

45 Mechanism-based inhibitors such as cycloserine and gabaculine can inactivate aminotransfera

46 mbined with data from previous trials with D-cycloserine and glycine, suggest that agonists at the gl

47 reacts with the nucleophilic serine and that cycloserine and lactone rings of LTV are opened.

48 no overall differences in symptoms between D-cycloserine and placebo at any time.

49 differences between glycine and placebo or D-cycloserine and placebo subjects on the average cognitio

50 re between glycine and placebo subjects or D-cycloserine and placebo subjects.

51 pressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glu

52 rtial agonists at the NMDA coagonist site, d-cycloserine and rapastinel, significantly reduced depres

53 g effects of extended training, as well as d-cycloserine and yohimbine treatment.

54 ncomycin, ristocetin), peptides (bacitracin, cycloserine), and chloramphenicol were found to differ s

55 e synthesis, fumonisin B(1), myriocin, and l-cycloserine, and 4-HPR transiently activated serine palm

56 Glycine site agonists were glycine, D-cycloserine, and aminocyclopropane-carboxylic acid.

57 acin, ethionamide, para-aminosalicylic acid, cycloserine, and linezolid.

58 ctamase in M. xanthus, such as ampicillin, D-cycloserine, and phosphomycin, accelerates the onset of

59 d loss of function conferred resistance to D-cycloserine, and susceptibility to the drug was partiall

60 lyzed) treated with fosfomycin, D-boroAla, D-cycloserine, and vancomycin.

61 D-cycloserine appears to enhance the benefits of exposure

62 upport for the use of short-term dosing of d-cycloserine as an adjunctive intervention to exposure th

63 These data provide support for the use of D-cycloserine as an augmentation of behavior therapy for O

64 nking, and support testing of D-serine and D-cycloserine as immediately accessible, FDA-approved drug

65 d consecutive 2-week trials of placebo and D-cycloserine at 5, 15, 50, and 250 mg/day.

66 ions at baseline or with concentrations of D-cycloserine at weeks 4 and 8.

67 d-cycloserine augmentation of CBT did not confer additiona

68 D-cycloserine augmentation reduced cortisol and startle re

69 D-Cycloserine-augmented and placebo-augmented CBT were ass

70 0 min, followed by inoculation onto modified cycloserine cefoxitin fructose agar with and without hor

71 for 10 min before inoculation onto modified cycloserine, cefoxitin, and fructose agar with horse blo

72 Cycloserine-cefoxitin fructose agar (CCFA), CCFA with ho

73 horse blood and taurocholate (CCFA-HT), and cycloserine-cefoxitin mannitol broth with taurocholate a

74 have developed a reduced-cost substitute for cycloserine-cefoxitin-fructose agar (CCFA), which is an

75 e produced by Clostridium difficile grown on cycloserine-cefoxitin-fructose agar (CCFA).

76 dvanced Clinical Diagnostics) and culture on cycloserine-cefoxitin-fructose agar followed by determin

77 iated disease were prospectively cultured on cycloserine-cefoxitin-fructose agar following alcohol sh

78 cile spores, at a rate comparable to that in cycloserine-cefoxitin-fructose broth.

79 X-ray structure of the MGL.l-cycloserine complex has been solved at 1.6 A resolution.

80 e precursors isolated after treatment with d-cycloserine consisted entirely of N-glycolyl muropeptide

81 isolated from M. tuberculosis treated with d-cycloserine contained only N-glycolylmuramyl-tripeptide

82 Thus, we wondered if d-cycloserine could improve sociability in 4-week old Balb

83 glutamic acid, aspartyl-histidine (Asp-His), cycloserine (cSer), and arginine, which provided a stepw

84 Chlamydia growth is inhibited by D-cycloserine (DCS) and in vitro analysis provided evidenc

85 ine and D-serine (DS), the partial agonist D-cycloserine (DCS) and the antagonist 5,7-dichlorokynuren

86 Whether and under which conditions D-cycloserine (DCS) augments the effects of exposure-based

87 d-Cycloserine (DCS) is a broad-spectrum antibiotic that in

88 D-cycloserine (DCS) is an N-methyl-D-aspartate (NMDA) rece

89 effects of enhancing NMDAR signaling using d-cycloserine (DCS) on a recently developed LTP EEG paradi

90 ear evidence for an augmentation effect of D-cycloserine (DCS) on exposure therapy for anxiety disord

91 ory processes, whereas the partial agonist D-cycloserine (DCS) potentiates both learning and extincti

92 ntextual fear conditioning was reversed by D-Cycloserine (DCS) treatment.

93 nxiety disorders, the supplementary use of D-cycloserine (DCS), a partial agonist at the glutamatergi

94 Here we evaluate the ability of D-cycloserine (DCS), a partial agonist at the strychnine-i

95 tracellular Mg2+ concentration or applying d-cycloserine (DCS), a partial agonist of the GluN glycine

96 Specifically, D-cycloserine (DCS), a partial agonist of the NMDA-associa

97 nction have resulted in the development of d-cycloserine (DCS), a partial glutamatergic N-methyl-D-as

98 It is unclear whether d-cycloserine (DCS), a partial N-methyl-d-aspartate agonis

99 riments with rat subjects examined whether D-cycloserine (DCS), a partial NMDA agonist, facilitates t

100 The effect of D-cycloserine (DCS), an NMDA partial agonist, on extinctio

101 ive efficacies of NR1 agonists glycine and d-cycloserine (DCS), and found efficacy to be dependent on

102 s to determine if a novel pharmacotherapy, D-cycloserine (DCS), enhanced the efficacy of the psychoth

103 of the glycineB receptor partial agonist, D-cycloserine (DCS), has been shown to enhance the consoli

104 We tested the hypothesis that d-cycloserine (DCS), which enhances extinction in other pr

105 Moreover, D-cycloserine (DCS), which facilitates fear extinction, se

106 In this regard, administration of d-cycloserine (DCS), which is a glycine site NMDA receptor

107 ation of the NMDA receptor partial agonist D-cycloserine (DCS).

108 The effects of daily D-cycloserine (DCS; a partial agonist of the NMDA receptor

109 D-Cycloserine did not augment a full course of comprehensi

110 were administered three different doses of D-cycloserine during each of three 2-week periods.

111 analyses, alprazolam impaired recovery and D-cycloserine enhanced virtual reality outcome in patients

112 D-Cycloserine exhibits partial agonist activity at the gly

113 ial of current formulations of glycine and D-cycloserine failed to show an overall benefit.

114 vivo by treating prediabetic ZDF rats with L-cycloserine for 2 weeks.

115 There was no advantage of D-cycloserine for PTSD symptoms in primary analyses.

116 Seven dropouts occurred in the D-cycloserine group and 1 in the placebo group.

117 At posttreatment, the D-cycloserine group had the lowest cortisol reactivity and

118 tment-specific enhancer of outcome for the D-cycloserine group only.

119 ly more improved at mid-treatment, and the D-cycloserine group's depressive symptoms were significant

120 Relative to the placebo group, the D-cycloserine group's OCD symptoms were significantly more

121 These results show that at low doses, D-cycloserine has cognition-enhancing properties in this m

122 D-Cycloserine has cognitive benefits for patients with Alz

123 d-cycloserine has the therapeutic properties of a desired

124 ursodeoxycholic acid, tryptophan, L-valine, cycloserine, hypoxanthine, and 4-O-Methylmelleolide conc

125 d-Cycloserine improved measures of impaired sociability in

126 tive symptoms, whereas the partial agonist D-cycloserine improved negative symptoms of patients takin

127 Thus, d-cycloserine improves both sociability and stereotypic be

128 ant M. smegmatis strains were inhibited by D-cycloserine in a concentration-dependent manner.

129 Participants receiving d-cycloserine in addition to exposure therapy reported sig

130 Further controlled studies of D-cycloserine in autism appear warranted.

131 f the transaminase pathway) in the case of d-cycloserine, in contrast to results obtained using the w

132 We additionally report the L- and D-cycloserine inactivated crystal structures of Bacillus s

133 tic adduct, a scheme similar to that seen in cycloserine inactivation of aminotransferases.

134 illus stearothermophilus alanine racemase on cycloserine inactivation.

135 transport, whereas d-alanine, glycine, and d-cycloserine inhibit CycA-mediated d-serine transport.

136 intake of quinine-adulterated alcohol, and D-cycloserine inhibited NAcore HA-NMDARs in vitro.

137 The chemical means by which cycloserine inhibits alanine racemase is unknown.

138 These observations indicate that cycloserine inhibits alanine racemase production of D-Al

139 y results suggest that neither glycine nor D-cycloserine is a generally effective therapeutic option

140 Cycloserine is a known alanine racemase suicide substrat

141 D-cycloserine is an antibiotic which targets sequential ba

142 D-Cycloserine is an effective second-line drug against Myc

143 D-cycloserine is associated with a small augmentation effe

144 We have shown that cell wall stress (e.g. d-cycloserine) is a potent inducer of the algD operon.

145 onists or antagonists, namely (+/-)HA-966, D-cycloserine, MDL-29,951, DPCQ, MNQX or L-701 252 were ab

146 oligonucleotides covalently attached to a D-cycloserine molecule, whereby entry into the mycobacteri

147 When strain PAO1 was exposed to d-cycloserine, MucA was degraded within just 10 min, and s

148 either 250 mg of the partial NMDA agonist d-cycloserine (n=20) or matching placebo capsules (n=27).

149 or characterization of the in vivo effect of cycloserine on Escherichia coli.

150 There was a significant dose effect of D-cycloserine on scores on the Scale for the Assessment of

151 In the present study, the effects of D-cycloserine on spatial short-term memory deficits in mon

152 The authors assessed the effects of D-cycloserine on the core symptom of social impairment in

153 re, we examined the impact of D-serine and D-cycloserine on this aversion-resistant alcohol intake (t

154 l-Cycloserine, on the other hand, utilizes a number of alt

155 of virtual reality exposure augmented with D-cycloserine or alprazolam, compared with placebo, in red

156 ol (as compared to ethambutol alone) or as D-cycloserine or biotin covalent adducts without the prese

157 de substrate was eliminated by addition of d-cycloserine or blocked by addition of vancomycin.

158 were randomly assigned to receive 50 mg of D-cycloserine or placebo 1 hour before each of five exposu

159 ion, participants received single doses of d-cycloserine or placebo.

160 ized clinical trial of adjunctive glycine, D-cycloserine, or placebo conducted at four sites in the U

161 In addition, D-cycloserine, phosphomycin, and hen egg-white lysozyme al

162 al Impressions-Severity indicated that the d-cycloserine plus CBT group and the placebo plus CBT grou

163 ed in a 1:1 ratio to either 10 sessions of d-cycloserine plus CBT or placebo plus CBT.

164 re randomized in a double-blind fashion to d-cycloserine plus CBT or placebo plus CBT.

165 sed and compared with previous results for D-cycloserine plus conventional neuroleptics.

166 Treatment of EAE mice with l-cycloserine prevented the increase in C(16:0)-Cer and iN

167 A966 and clonidine, but not propranolol or D-cycloserine, prevented FG7142-associated spatial working

168 The improvement of negative symptoms with D-cycloserine previously observed in patients receiving ty

169 alanine:D-alanine ligase by the antibiotic D-cycloserine proceeds via a distinct phosphorylated form

170 -week old Swiss Webster mice; furthermore, d-cycloserine reduced their intensity.

171 he SANS total score for patients receiving D-cycloserine relative to patients receiving placebo.

172 Serum concentrations of D-cycloserine, relevant amino acids, and homovanillic acid

173 We also show that D-cycloserine rescues the cognitive deficits observed in f

174 overproduction is a potential mechanism of D-cycloserine resistance in clinical isolates of M. tuberc

175 results show that one of the mechanisms of D-cycloserine resistance in M. smegmatis involves the over

176 To analyze the genetic determinants of D-cycloserine resistance in mycobacteria, a library of a r

177 Incorporation of D-cycloserine resistance in novel molecular diagnostics co

178 The D-cycloserine resistance phenotype in the recombinant clon

179 A was necessary and sufficient to confer a D-cycloserine resistance phenotype.

180 Cycloserine resulted in a dramatic lowering of both D-Al

181 ing NMDAR function with the NMDAR co-agonist cycloserine reversed electrophysiological and behavioral

182 al derivative (arising from either isomer of cycloserine) saturated at the C4' carbon position.

183 12 via CycA, the d-alanine transporter and d-cycloserine sensitivity locus.

184 D-cycloserine shifted decision-making towards a more optim

185 ne in a multicopy vector were resistant to D-cycloserine, suggesting that AlrA overproduction is a po

186 resulted in poor induction of PalgD-cat by D-cycloserine, suggesting that it also plays a role in the

187 atic assays using recombinant proteins and D-cycloserine susceptibility indicate that the A365V mutat

188 D-serine and D-cycloserine, the NMDAR activators at the glycine site, a

189 t neither extended extinction training nor d-cycloserine treatment improved 129S1 extinction.

190 In this pilot study, D-cycloserine treatment resulted in significant improvemen

191 ation of the NMDA receptor partial agonist D-cycloserine, under the same behavioural conditions, did

192 posed to low concentrations of fosfomycin, d-cycloserine, vancomycin, and nisin, indicating a wide-sp

193 nd, placebo-controlled trial investigating D-cycloserine versus placebo augmentation of behavior ther

194 Although D-cycloserine was associated with a 24%-33% faster rate of

195 D-Cycloserine was associated with significant improvement

196 A prosocial effect of d-cycloserine was observed at a dose as low as 32.0mg/kg i

197 with glycine, l-alanine, l-norvaline, and l-cycloserine was performed by pre-steady-state stopped-fl

198 Enrichment with D-cycloserine was used to identify Escherichia coli auxotr

199 d-Cycloserine was well tolerated at most of the doses used

200 As a result, fosfomycin and D-cycloserine were added to the group of peptidoglycan syn

201 and alr exhibited increased resistance to D-cycloserine when cultured in vitro.

202 D-cycloserine, when paired with familiarity training sessi

203 activity was partially (64%) inhibited by D-cycloserine, whereas host alanine racemase activity was

204 which blocks palmitoyl-CoA synthesis, and L-cycloserine, which blocks SPT activity, completely block

205 ound that overlapped with genes induced by d-cycloserine, which is known to activate algD expression.